Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as C$0.06 and last traded at C$0.06, with a volume of 117018 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The stock’s 50 day moving average is C$0.07 and its two-hundred day moving average is C$0.08. The firm has a market capitalization of C$11.31 million, a P/E ratio of -2.22 and a beta of 0.59. The company has a debt-to-equity ratio of -72.45, a current ratio of 0.49 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Featured Articles
- Five stocks we like better than Hemostemix
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
